← All Sponsors
SPONSOR

Shanghai Allink Biotherapeutics Co., Ltd.

Total Trials
1
Recruiting
1
Phases
Phase 1
Conditions studied: Advanced CancerAdvanced Solid Tumor
NCT06707610 Phase 1
Recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK202 in Participants with Advanced Solid Tumors

Advanced Cancer
United States, Australia View Trial →